Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease

We have previously demonstrated amelioration of Huntington's disease (HD)-related phenotypes in R6/2 transgenic mice in response to treatment with the novel histone deacetylase (HDAC) inhibitor 4b. Here we have measured the selectivity profiles of 4b and related compounds against class I and class I...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Haiqun Jia, Judit Pallos, Vincent Jacques, Alice Lau, Bin Tang, Andrew Cooper, Adeela Syed, Judith Purcell, Yi Chen, Shefali Sharma, Gavin R. Sangrey, Shayna B. Darnell, Heather Plasterer, Ghazaleh Sadri-Vakili, Joel M. Gottesfeld, Leslie M. Thompson, James R. Rusche, J. Lawrence Marsh, Elizabeth A. Thomas
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2012-05-01
סדרה:	Neurobiology of Disease
נושאים:	Neurodegenerative Striatum Disease Epigenetic Therapeutic Chromatin
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S096999611200040X
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!